New Publication Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective
The NMD4C is proud to announce that a Guidance on gene replacement therapy in Spinal Muscular Atrophy: a Canadian perspective has been accepted for publication by the Canadian Journal of Neurological Sciences. Notably this consensus statement is authored by NMD4C members Drs. Maryam Oskoui, Hernan Gonorazky, Hugh McMillan, James Dowling, Reshma Amin, Cynthia Gagnon, and Kathryn Selby.
This publication is the first significant research output of the NMD4C, and is a product of the network’s development, dissemination, and implementation of clinical guidelines working group. The working group invited pediatric neuromuscular clinical experts from across the country to provide feedback and direction in adapting existing consensus statements on gene replacement therapy in SMA to the Canadian context.
“It is an exciting time for the neuromuscular field with the advancement of gene therapies. It is our duty as neuromuscular specialists to advocate for safe, equitable, and transparent access to these treatments for all Canadians. We hope that through this consensus we can help inform the application, indication and use of gene replacement therapy in Spinal muscular atrophy.”
– Dr. Hernan Gonorazky.
You can find the publication here.
With three SMA therapies now commercially available in Canada, the working group set out to provide guidance by adapting a set of European consensus statements to a Canadian context and highlighting areas of future need for gene replacement therapy in SMA in Canada. The original publication from an ad-hoc group of 13 European SMA experts who published a set of consensus statements on the use of gene replacement therapy in SMA using a Delphi consensus process.
The NMD4C will continue to work towards its knowledge translation (KT) goals to improve care standards, train the next generation of neuromuscular researchers and clinicians, and strengthen research infrastructure for better research and more treatments.
Read next...
Defeat Duchenne Canada launches 2023 Research Grant Program
DDC invites research proposals for their 2023 research grant program of a translational or clinical nature focused on improving the health and quality of life for individuals living with Duchenne muscular dystrophy.
Investigator Dr. Maryam Oskoui Receives CIHR Grant to Fund Spinal Muscular Atrophy Clinical Trial
NMD4C investigator Dr. Maryam Oskoui was awarded a Canadian Institutes of Health Research Clinical Trials Operating Grant for INFORM SMA as nominated principal applicant.
Early Career member Dr. Jean-Philippe Leduc-Gaudet identifies gene involved in regulating autophagy and skeletal muscle integrity
NMD4C early career member, Dr. Jean-Philippe Leduc-Gaudet, has made a significant discovery by identifying a novel gene that plays a key role in regulating autophagy and skeletal muscle health
New CIHR-funded Burden of Inherited Neuromuscular Disease (BIND) Study: Assessing the Indirect Socio-Economic Burden of Inherited Neuromuscular Diseases
The BIND study’s goal is to assess the social and economic burden of Canadians living with neuromuscular disorders by using web-based surveys to assess quality-of-life, healthcare resource use, work productivity, and effect on schooling and careers.
Muscular Dystrophy Canada, Canadian Neuromuscular Disease Registry, NMD4C partner to ensure Canadians can access Facioscapulohumeral muscular dystrophy (FSHD) cure(s)
MDC and the CNDR are working together with NMD4C to introduce a patient registry and collect information to build a Canada-wide core dataset for FSHD.
NMD4C Announces 2023 Early Career Award Recipients
We are excited to announce the recipients of the inaugural NMD4C Early Career Investigator Awards for 2023! This annual award program introduces three new awards, celebrating excellence and contribution to the neuromuscular field by early career investigators across both clinical and basic science streams.